Mar 27, 2019 - Eli Lilly (LLY) gets an exclusive, worldwide license to develop and commercialize a novel immunometabolism target from private biotech, ImmuNext.
Apr 02, 2019 - Merck's (MRK) Keytruda receives approval for treating nonsquamous non-small cell lung cancer in combination with chemotherapies in first-line setting in China.
Apr 09, 2019 - United Therapeutics (UTHR) discontinues the development of esuberaprost, as the phase III study fails to meet primary endpoint.
Apr 10, 2019 - Top Stock Reports for Eli Lilly, Altria & Becton Dickinson
Apr 15, 2019 - FDA grants approval to J&J's (JNJ) erdafitinib for metastatic urothelial cancer, a type of bladder cancer. This is J&J's second FDA approval for a new drug in less than two months
Apr 25, 2019 - Bayer (BAYRY) exceeds earnings estimates in the first quarter of 2019 and sales rise year over year.
Apr 28, 2019 - So far, the going seems good for the drug/biotech sector this earnings season. Let us take a glance at a few other companies, which hold promise to beat on Q1 earnings.
Apr 30, 2019 - While Incyte's (INCY) earnings and revenues beat estimates in Q1, Jakafi sales fall short of the same.
Apr 30, 2019 - Let's check out three tech stocks that came through our screen today that growth investors might want to consider at the moment...
May 01, 2019 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.